Literature DB >> 25201939

Primary care physicians' use of FDA-approved prescription drug labels.

Helen W Sullivan1, Amie C O'Donoghue2, Kathryn J Aikin2.   

Abstract

BACKGROUND: In 2006, the US Food and Drug Administration reorganized the approved label format and content for prescription drugs -also known as the prescribing information (PI). This research examines primary care physicians' use of the new PI and how it may influence their perceptions about prescription drugs.
METHODS: A total of 500 physicians responded to an Internet survey that displayed an interactive PI for a fictitious combination pain relief/heart attack-reducing drug. The physicians answered questions about perceived risk, perceived benefit, and intention to prescribe that focused on either the treatment indication or the prevention indication.
RESULTS: Physicians viewed PI sections in order, most often viewing sections relevant to safe use, such as Warnings and Precautions and Dosage and Administration. When asked to think about the drug's efficacy, many viewed the Clinical Studies section. Viewing certain PI sections was associated with greater perceived risk and lower perceived benefits and intention to prescribe.
CONCLUSIONS: These results suggest that the information in the PI could affect physician decision making and do not support further reorganization of the PI. © Copyright 2014 by the American Board of Family Medicine.

Entities:  

Keywords:  Drug Labeling; Prescription Drugs

Mesh:

Substances:

Year:  2014        PMID: 25201939     DOI: 10.3122/jabfm.2014.05.140039

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  3 in total

1.  Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.

Authors:  P C Mathias; N Hendrix; W-J Wang; K Keyloun; M Khelifi; P Tarczy-Hornoch; B Devine
Journal:  Clin Pharmacol Ther       Date:  2017-06-05       Impact factor: 6.875

2.  Physicians' use of and preferences for FDA-approved prescribing information.

Authors:  Helen W Sullivan; Claudia Squire; Kathryn J Aikin; Janice Tzeng; Kate Ferriola-Bruckenstein; Eric Brodsky; Ann Marie Trentacosti; Mihaela Johnson
Journal:  Res Social Adm Pharm       Date:  2021-08-01

3.  Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders.

Authors:  Anne Vinther Morant; Vivien Jagalski; Henrik Tang Vestergaard
Journal:  Front Med (Lausanne)       Date:  2019-10-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.